You just read:

Novartis' Mayzent and EMD Serono's Mavenclad Look to Dethrone Genentech's Ocrevus in the Expanding Patient Segment of Active Secondary Progressive Multiple Sclerosis

News provided by

Spherix Global Insights

Nov 14, 2019, 08:00 ET